Giannis Mountzios, Director of 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared on X:
“ELCC25 MARIPOSA trial OS in 1L EGFR-mutant NSCLC:
Ami+Laze vs Osi:
- mOS NR vs 36.7 m
- HR 0.79 for CNS progression
- median ic DoR 35.7 months
- projected OS benef> 12 months
- prophylactic anticoagulant and Steroid for iRR
Game changer in 1L. Patients with co-mutations?”
